Source: International Congress 2018 – Challenges in tuberculosis care
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
D. Butov (Kharkiv, Ukraine), M. Kuzhko (Kiev, Ukraine), G. Stepanenko (Kharkiv, Ukraine), T. Butova (Kharkiv, Ukraine). Frequency of adverse reactions to first-line anti-tuberculosis chemotherapy in patients with relapse(RTB)and newly diagnosed tuberculosis(NDTB). 2700

Member's Comments

No comment yet.

Related content which might interest you: Adverse events in patients with MDR TB, treated by three types of the chemotherapy regimens Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019 Clinical efficacy of new anti-TB drug ²tubelon² during complex chemotherapy in patients with first-time diagnosed destuctive pulmonary TB Source: Eur Respir J 2006; 28: Suppl. 50, 8s Year: 2006 Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 650s Year: 2005 Predictive role of MMP-2 genetic variants on severe hematologic toxicity of NSCLC patients treated with first-line, platinum-based chemotherapy Source: Annual Congress 2011 - Genetics of airway diseases and treatment Year: 2011 Secondary drug resistance during an intravenous intermittent chemotherapy in newly cases TB Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011 Adverse effects in patients receiving therapy for multi-drug resistant tuberculosis in Latvia Source: Eur Respir J 2003; 22: Suppl. 45, 41s Year: 2003 Adverse effects of anti-tuberculosis drugs in hemodialysis patients Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019 Chemotherapy efficacy in TB patients resistant to major and reserve drugs Source: Eur Respir J 2005; 26: Suppl. 49, 648s Year: 2005 The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Impact of drug resistance over sputum conversion in tubercular patients receiving re-treatment regimen Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011 Management of adverse drug events in TB therapy Source: Eur Respir Mon 2012; 58: 167-193 Year: 2012 Characteristics of patients who interrupted anti-tuberculosis treatment Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis Year: 2008 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis Source: Eur Respir J 2006; 28: Suppl. 50, 128s Year: 2006 The clinical characteristics and treatment responses of tuberculosis in patients with malignancy on anti-cancer chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 690s Year: 2005 The incidence of adverse reactions in anti-tuberculosis chemotherapy in S-W Romania Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011 Short-term efficacy of advanced NSCLC patients receiving anlotinib hydrochloride as the first and second-line treatment Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Adverse drug reactions and outcomes of tuberculosis treatment using fixed-dose combination (FDC) regimen Source: Annual Congress 2012 - Tuberculosis: clinical findings I Year: 2012 Efficacy of a standard chemotherapy regimen in the management of sputum-positive pulmonary TB relapses Source: Eur Respir J 2003; 22: Suppl. 45, 41s Year: 2003